- Feb 14, 2020
- 1,630
- Tinnitus Since
- 1-2019
- Cause of Tinnitus
- 20+ Years of Live Music, Motorcycles, and Power Tools
Oh, I totally agree with you over the long-term. I'm speaking to expectations on what the drug we're talking about today is being positioned for. They're also speaking simply on what is known about the Phase 1/2.One thing that I would note from your comment is that while the CEO David Lucchino has indicated that there is a likelihood some people will still need a hearing aid after FX-322 due to it not going deep enough into the cochlea, I would still not rule out that they would not possibly work out a way to get the medicine deeper in the future.
The information which Frequency Therapeutics has released has always actually ended up being ultra conservative because they simply cannot risk falling afoul of the FDA rules. Therefore I equally wouldn't be surprised if Frequency Therapeutics was also being very cautious in commenting about the benefits of FX-322.
I refer back to where Frequency Therapeutics stated something along the lines that they didn't think FX-322 was going to be the medicine which would actually end up providing full regrowth, but that there are some pretty clever drug delivery guys so who actually knows what may end up happening. This tells me that the need to use FX-322 with hearing aids may not actually end up being a long term thing.
There could be every chance that I am wrong, however this gives me the impression that Frequency Therapeutics might actually go down the path of getting FX-322 out ASAP and work improving the benefit it can provide later on. This way Frequency Therapeutics can start assisting patients ASAP and work with improving things later.
If they show results that say the 4X dose group in the Phase 2A saw improvements down the 4 kHz or lower; the communications will change dramatically.
The best business case for FX-322 is to get the product producing revenue in its current state, even if it can't restore hearing completely. Having true cash flow gives them the ability to reinvest in the product development and expand into other hearing loss - related issues.
Lucchino has said that they intend for the drug to restore all hearing. I think it's just a matter of time (and money).